Association between history of HBV vaccine response and anti-SARS-CoV-2 spike antibody response to the BioNTech/Pfizer’s BNT162b2 mRNA SARS-CoV-2 vaccine among healthcare workers in Japan: A prospective observational study
Fig 1
Spike protein antibody levels of patients in the study.
(A) Distribution of SARS-CoV-2 spike protein antibody titers (logarithmic scale) at baseline, after one dose of BNT162b2 mRNA-1273 COVID-19 vaccine, and after two doses (n = 954). (B) Distribution of SARS-CoV-2 spike protein antibody titers (logarithmic scale) after a single dose of BNT162b2 mRNA-1273 COVID-19 vaccine, stratified by age groups (n = 954). (C) Distribution of SARS-CoV-2 spike protein antibody titers (logarithmic scale) after a single dose of BNT162b2 mRNA-1273 COVID-19 vaccine, stratified by history of HBV vaccine response (n = 954).